4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy
Single-cell RNA-seq · human · 87 samples
- What it is
- Single-cell RNA-seqGene activity measured in thousands of individual cells, so cell types can be told apart. Read from the summary: GEO's own type field only says 'expression profiling by sequencing', so confirm it in the paper.
- Organism
- Homo sapiens (human)
- Samples
- 87 samples: 87 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- 4-1BB(+) Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapyCell reports. Medicine · 2025
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE286827_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Single-cell studies usually ship their counts as 10x files (matrix.mtx, barcodes.tsv, features.tsv), an .h5 file, or an .rds / .h5ad object that Seurat or Scanpy can open. Look for those among the supplementary files.
Also filed as BioProject PRJNA1209997 and SRA study SRP557129. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 87 sample titles: 87 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8730271 P1_pre_GEX
- GSM8730272 P1_post_GEX
- GSM8730273 P2_pre_GEX
- GSM8730274 P2_post_GEX
- GSM8730275 P3_post_GEX
- GSM8730276 P4_pre_GEX
- GSM8730277 P4_post_GEX
- GSM8730278 P5_pre_GEX
- GSM8730279 P5_post_GEX
- GSM8730280 P6_pre_GEX
- GSM8730281 P6_post_GEX
- GSM8730282 P8_pre_GEX
- GSM8730283 P8_post_GEX
- GSM8730284 P8_post2_GEX
- GSM8730285 P9_pre_GEX
- GSM8730286 P9_post_GEX
- GSM8730287 P11_pre_GEX
- GSM8730288 P11_post_GEX
- GSM8730289 P12_pre_GEX
- GSM8730290 P12_post_GEX
- GSM8730291 P13_pre_GEX
- GSM8730292 P13_post_GEX
- GSM8730293 P14_pre_GEX
- GSM8730294 P14_post_GEX
- GSM8730295 P15_pre_GEX
- GSM8730296 P15_post_GEX
- GSM8730297 P16_pre_GEX
- GSM8730298 P16_post_GEX
- GSM8730299 P18_pre_GEX
- GSM8730300 P18_post_GEX
- GSM8730301 P19_pre_GEX
- GSM8730302 P19_post_GEX
- GSM8730303 P20_pre_GEX
- GSM8730304 P20_post_GEX
- GSM8730305 P22_pre_GEX
- GSM8730306 P22_post_GEX
- GSM8730307 P23_pre_GEX
- GSM8730308 P23_post_GEX
- GSM8730309 P24_pre_GEX
- GSM8730310 P24_post_GEX
+ 47 more — browse all 87 samples with per-sample file links →
- GSE272734 Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells [dataset 2] 40 samples shares anti-ctla-4, combination, progenitor, exhausted
- GSE272993 Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells [dataset 1] 360 samples shares anti-ctla-4, combination, progenitor, exhausted
- GSE302752 Safety, feasibility and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab 76 samples shares 4-1bb, combination
- GSE271668 Phase 1 trial of durvalumab (anti-PD-L1) in combination with lenalidomide in relapsed/refractory cutaneous T cell lymphoma 24 samples shares anti-pd-l1, combination
- GSE313827 Dysregulation of the Hippo Pathway in Cancer Associated Fibroblasts is Associated with anti-PD-L1 atezolizumab Resistance 18 samples shares anti-pd-l1, resistance
- GSE225061 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response 217 samples shares combination, resistance
- GSE250032 Combination of a SOS1-KRAS interaction inhibitor with a KRASG12C inhibitor combination can address intrinsic and acquired resistance leading to stronger and more durable response (Quant-Seq 2) 65 samples shares combination, resistance
- GSE339038 RNA-Seq of CD3+ T cells flow sorted from MLR assays with TNF/TNFR inhibitory compound combination treatments 64 samples shares combination, inhibitory
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.